1. Home
  2. FNWD vs CGEN Comparison

FNWD vs CGEN Comparison

Compare FNWD & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Finward Bancorp

FNWD

Finward Bancorp

HOLD

Current Price

$36.41

Market Cap

155.0M

Sector

Finance

ML Signal

HOLD

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$2.10

Market Cap

148.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNWD
CGEN
Founded
1994
1993
Country
United States
Israel
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
155.0M
148.7M
IPO Year
1996
2001

Fundamental Metrics

Financial Performance
Metric
FNWD
CGEN
Price
$36.41
$2.10
Analyst Decision
Buy
Strong Buy
Analyst Count
1
1
Target Price
$34.00
$4.00
AVG Volume (30 Days)
4.2K
308.3K
Earning Date
04-28-2026
01-01-0001
Dividend Yield
1.31%
N/A
EPS Growth
44.90
N/A
EPS
1.42
N/A
Revenue
N/A
N/A
Revenue This Year
$17.40
N/A
Revenue Next Year
$5.44
$58.57
P/E Ratio
$25.70
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.46
$1.13
52 Week High
$39.99
$2.38

Technical Indicators

Market Signals
Indicator
FNWD
CGEN
Relative Strength Index (RSI) 51.99 59.74
Support Level $36.37 $1.45
Resistance Level $38.75 $2.38
Average True Range (ATR) 1.02 0.15
MACD -0.04 0.04
Stochastic Oscillator 64.55 67.56

Price Performance

Historical Comparison
FNWD
CGEN

About FNWD Finward Bancorp

Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: